Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Defending against smallpox: a focus on vaccines.

Voigt EA, Kennedy RB, Poland GA.

Expert Rev Vaccines. 2016 Sep;15(9):1197-211. doi: 10.1080/14760584.2016.1175305. Epub 2016 Apr 28. Review.

2.

Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.

Matho MH, Schlossman A, Meng X, Benhnia MR, Kaever T, Buller M, Doronin K, Parker S, Peters B, Crotty S, Xiang Y, Zajonc DM.

PLoS Pathog. 2015 Sep 1;11(9):e1005148. doi: 10.1371/journal.ppat.1005148. eCollection 2015 Sep.

3.

DNA immunization.

Wang S, Lu S.

Curr Protoc Microbiol. 2013 Nov 5;31:18.3.1-18.3.24. doi: 10.1002/9780471729259.mc1803s31.

4.

Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.

Paran N, Lustig S, Zvi A, Erez N, Israely T, Melamed S, Politi B, Ben-Nathan D, Schneider P, Lachmi B, Israeli O, Stein D, Levin R, Olshevsky U.

Virol J. 2013 Jul 10;10:229. doi: 10.1186/1743-422X-10-229.

5.

Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Xiao Y, Zeng Y, Alexander E, Mehta S, Joshi SB, Buchman GW, Volkin DB, Middaugh CR, Isaacs SN.

Vaccine. 2013 Jan 2;31(2):319-26. doi: 10.1016/j.vaccine.2012.11.007. Epub 2012 Nov 12.

6.

Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

Townsend MB, Keckler MS, Patel N, Davies DH, Felgner P, Damon IK, Karem KL.

J Virol. 2013 Jan;87(2):900-11. doi: 10.1128/JVI.02089-12. Epub 2012 Nov 7.

7.

A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.

Verardi PH, Titong A, Hagen CJ.

Hum Vaccin Immunother. 2012 Jul;8(7):961-70. doi: 10.4161/hv.21080. Epub 2012 Jul 1. Review.

8.

Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.

Golden JW, Zaitseva M, Kapnick S, Fisher RW, Mikolajczyk MG, Ballantyne J, Golding H, Hooper JW.

Virol J. 2011 Sep 20;8:441. doi: 10.1186/1743-422X-8-441.

9.

Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens.

Miller L, Richter M, Hapke C, Stern D, Nitsche A.

PLoS One. 2011;6(7):e21950. doi: 10.1371/journal.pone.0021950. Epub 2011 Jul 14.

10.

Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

Keckler MS, Carroll DS, Gallardo-Romero NF, Lash RR, Salzer JS, Weiss SL, Patel N, Clemmons CJ, Smith SK, Hutson CL, Karem KL, Damon IK.

J Virol. 2011 Aug;85(15):7683-98. doi: 10.1128/JVI.02174-10. Epub 2011 Jun 1.

11.

The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Kennedy RB, Poland GA.

Virology. 2010 Dec 20;408(2):232-40. doi: 10.1016/j.virol.2010.09.013. Epub 2010 Oct 18.

12.
13.

Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Powell RL, Kinge T, Nyambi PN.

J Virol. 2010 Sep;84(18):9415-26. doi: 10.1128/JVI.02732-09. Epub 2010 Jul 14.

14.

Technical transformation of biodefense vaccines.

Lu S, Wang S.

Vaccine. 2009 Nov 5;27 Suppl 4:D8-D15. doi: 10.1016/j.vaccine.2009.08.055. Review.

15.

Smallpox vaccines for biodefense.

Kennedy RB, Ovsyannikova I, Poland GA.

Vaccine. 2009 Nov 5;27 Suppl 4:D73-9. doi: 10.1016/j.vaccine.2009.07.103. Review.

16.

New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.

Borovkov A, Magee DM, Loskutov A, Cano JA, Selinsky C, Zsemlye J, Lyons CR, Sykes K.

Virology. 2009 Dec 5;395(1):97-113. doi: 10.1016/j.virol.2009.09.008. Epub 2009 Oct 2.

17.

The immunology of smallpox vaccines.

Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA.

Curr Opin Immunol. 2009 Jun;21(3):314-20. doi: 10.1016/j.coi.2009.04.004. Epub 2009 Jun 11. Review.

18.

The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Duke-Cohan JS, Wollenick K, Witten EA, Seaman MS, Baden LR, Dolin R, Reinherz EL.

Vaccine. 2009 Feb 18;27(8):1154-65. doi: 10.1016/j.vaccine.2008.12.035. Epub 2009 Jan 13.

19.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

Supplemental Content

Support Center